|Bid||33.60 x 100|
|Ask||33.67 x 1000|
|Day's Range||33.61 - 33.93|
|52 Week Range||27.74 - 36.34|
|PE Ratio (TTM)||198.94|
|Earnings Date||May 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.44|
QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.
QIAGEN N.V. announced today that its QuantiFERON-TB® Gold Plus , the gold standard in accurate, cost-effective testing for latent tuberculosis infection, has been endorsed for immigration medical screening by the International Panel Physicians Association .
Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge, cell-free DNA assays for use on QIAGEN's GeneReader NGS System. Natera's Constellation™ software would also be accessible for users of these and other assays in combination with the QIAGEN Clinical Insights (QCI) bioinformatics solution.
QIAGEN N.V. , a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. , a leading developer of next-generation sequencing assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge cell-free DNA assays for use on QIAGEN’s GeneReader NGS System.
QIAGEN N.V. today endorsed new guidelines issued by the World Health Organization , which coordinates global efforts to control tuberculosis , calling for harmonization of preventive screening and treatment of latent TB infection among vulnerable groups in countries with a high disease burden, as well as in low-burden countries.
Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.
Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.
QIAGEN N.V. announced today that it welcomed a decision by the U.S. Centers for Disease control to require the use of modern blood-based tests for tuberculosis screening.
Stock Monitor: National Research Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 16, 2018 / Active-Investors.com has just released a free earnings report on QIAGEN N.V. (NYSE: QGEN ). If you ...
QIAGEN (QGEN) continues to strengthen Molecular Diagnostics business with focus on expanding QuantiFERON-TB Gold Plus customer base.
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.
QIAGEN N.V. today announced that Japan’s Ministry of Health Labor and Welfare has approved QuantiFERON®-TB Gold Plus as an in vitro diagnostic to detect tuberculosis infection.
QIAGEN N.V. today announced the European launch of its novel therascreen PITX2 RGQ PCR Kit, the first clinically validated DNA methylation assay that helps predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy.
On a per-share basis, the Venlo, Netherlands-based company said it had a loss of 18 cents. Earnings, adjusted for non-recurring costs, were 43 cents per share. The results topped Wall Street expectations. ...
VENLO, Netherlands , January 31, 2018 /PRNewswire/ -- Solid Q4 results as QIAGEN achieves full-year 2017 targets : Q4 2017: Net sales $ 396. 9 million (+8% actual, +5 % CER); adjusted net sales rise ...
New system launch planned for second half of 2018 with two CE-IVD molecular diagnostics, U.S. launch planned for 2019 and broad pipeline in development GERMANTOWN, Maryland and HILDEN, Germany , January ...
QIAGEN NV (NYSE:QGEN), a life sciences company based in Netherlands, saw a decent share price growth in the teens level on the NYSE over the last few months. With manyRead More...
Small market caps, attractive growth prospects and idiosyncratic product cycles among diagnostics companies can lead to valuation volatility while also creating attractive M&A opportunities. The Analyst ...